Skip to main content
. 2017 Mar 2;28(6):1912–1923. doi: 10.1681/ASN.2016070797

Table 1.

Characteristics of patients with ABMR according to two types: preexisting DSA and de novo DSA

Characteristics All Patients Preexisting Anti-HLA DSA ABMR De Novo Anti-HLA DSA ABMR P Value
n n=205 n n=103 n n=102
Recipient
 Age, yr, mean (SD) 205 47.16 (15.39) 103 47.75 (13.00) 102 46.56 (17.52) 0.53
 Men, n (%) 205 118 (57.56) 103 46 (44.66) 102 72 (70.59) <0.001
 ESRD causes, n (%) 205 103 102
  Glomerulonephritis 75 (36.59) 28 (27.18) 47 (46.08)
  Diabetes 16 (7.80) 6 (5.83) 10 (9.80)
  Polycystic kidney disease 10 (4.88) 3 (2.91) 7 (6.86)
  Tubulo-interstitial disease 29 (14.15) 24 (23.30) 5 (4.90)
  Hypertension 14 (6.83) 7 (6.80) 7 (6.86)
  Unknown 43 (20.97) 29 (28.16) 14 (13.73)
  Other 18 (8.78) 6 (5.82) 12 (11.77) <0.001
Donor
 Age, yr, mean (SD) 203 45.57 (17.15) 103 48.06 (14.56) 100 43.01 (19.20) 0.04
 Men, n (%) 203 109 (53.69) 103 57 (55.34) 100 52 (52.00) 0.37
 DD, n (%) 204 158 (77.45) 103 93 (90.29) 101 65 (64.36) <0.001
Immunology at the time of transplant
 HLA class of anti-HLA DSA, n 103 103
 Immunodominant class 1 49 49
 Immunodominant class 2 54 54
 DSA MFI, median [IQR] 4500 [1862–10,210] 4500 [1862–10,210]
Treatment at the time of transplant, n (%)
 Steroids 205 194 (94.63) 103 103 (100) 102 91 (89.22) <0.001
 Thymoglobulin 205 111 (54.15) 103 70 (67.96) 102 41 (40.20) <0.001
 Plasmapheresis 205 18 (8.78) 103 18 (17.48) 102 0 <0.001
 Anti-CD20 therapy 205 20 (9.76) 103 20 (19.42) 102 0 <0.001
 IVIG 205 69 (33.66) 103 61 (59.22) 102 8 (7.84) <0.001
 Baseline immunosuppression, n (%) 205 103 102
  Tacrolimus 131 (63.90) 89 (86.41) 42 (41.18) <0.001
  Cyclosporin 70 (34.15) 15 (14.56) 55 (53.92) <0.001
  Sirolimus 2 (0.98) 0 2 (1.96) 0.25
Follow-up, yr, mean (SD) 205 4.13 (2.52) 103 4.71 (2.42) 102 3.55 (2.50) 0.001
Graft loss, n (%) 205 86 (41.95) 103 30 (29.13) 102 56 (54.90) <0.001

—, patients in the de novo DSA ABMR have no DSA at the time of transplant; MFI, mean fluorescence intensity.